Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00688-18. doi: 10.1128/AAC.00688-18. Print 2018 Sep.

TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam.

Author information

1
Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università degli Studi dell'Aquila, L'Aquila, Italy.
2
Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy.
3
Department of Infectious Diseases, Cotugno Hospital, Naples, Italy.
4
Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Florence, Italy.
5
SOD Microbiologia e Virologia, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
6
Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Florence, Italy tommaso.giani@unifi.it.

Abstract

TEM-184, a novel TEM-derived extended-spectrum β-lactamase (ESBL), was isolated from an Escherichia coli ST354 clinical strain. Compared to TEM-1, TEM-184 contains the mutations Q6K, E104K, I127V, R164S, and M182T. Kinetic analysis of this enzyme revealed extended-spectrum activity against aztreonam in particular. TEM-184 was also susceptible to inhibitors, including clavulanic acid, tazobactam, and avibactam.

KEYWORDS:

ESBL; avibactam; inhibitors

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center